October 1, 2024

Figure S14 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer

Los puntos clave no están disponibles para este artículo en este momento.

Synergy and viability analysis of RP-6306 and gemcitabine combination in MCF7 parental, EDR, and EDR Palbo-R cells

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Chen et al. (Tue,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar